Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management
- PMID: 23827861
- PMCID: PMC3815445
- DOI: 10.1053/j.gastro.2013.06.052
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management
Abstract
Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood, which in part explains the lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.
Keywords: AIH; AIP; Autoimmune Disease; CA; CCA; CFTR; CRN; Cholangiocarcinoma; Cholestatic Liver Disease; ERCP; FISH; FXR; GBN; HCC; IAC; IBD; IL; Ig; Inflammatory Bowel Disease; JAK; LGD; LPC; LT; MAdCAM-1; MDR; MR; MRCP; PSC; T-helper; TLR; TNF; Th; Toll-like receptor; UC; UDCA; VAP-1; autoimmune hepatitis; autoimmune pancreatitis; carbohydrate antigen; cholangiocarcinoma; colorectal neoplasia; cystic fibrosis transmembrane conductance regulator; endoscopic retrograde cholangiopancreatography; farnesoid X receptor; fluorescence in situ hybridization; gallbladder neoplasia; hepatocellular carcinoma; immunoglobulin; immunoglobulin G4–associated cholangitis; inflammatory bowel disease; interleukin; janus kinase; liver transplant; low-grade dysplasia; lymphoplasmacytic; magnetic resonance; magnetic resonance cholangiopancreatography; mucosal addressin cellular adhesion molecule 1; multidrug resistance protein; primary sclerosing cholangitis; tumor necrosis factor; ulcerative colitis; ursodeoxycholic acid; vascular adhesion protein 1.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Primary sclerosing cholangitis: diagnosis, prognosis, and management.Clin Gastroenterol Hepatol. 2013 Aug;11(8):898-907. doi: 10.1016/j.cgh.2013.02.016. Epub 2013 Feb 27. Clin Gastroenterol Hepatol. 2013. PMID: 23454027 Free PMC article. Review.
-
Primary sclerosing cholangitis.Can J Gastroenterol. 2008 Aug;22(8):689-98. doi: 10.1155/2008/824168. Can J Gastroenterol. 2008. PMID: 18701947 Free PMC article. Review.
-
Imaging Features of Primary Sclerosing Cholangitis: From Diagnosis to Liver Transplant Follow-up.Radiographics. 2019 Nov-Dec;39(7):1938-1964. doi: 10.1148/rg.2019180213. Epub 2019 Oct 18. Radiographics. 2019. PMID: 31626561 Review.
-
Recent insights in primary sclerosing cholangitis.J Dig Dis. 2012 Jul;13(7):337-41. doi: 10.1111/j.1751-2980.2012.00605.x. J Dig Dis. 2012. PMID: 22713082 Review.
-
Primary sclerosing cholangitis.Recent Results Cancer Res. 2011;185:117-33. doi: 10.1007/978-3-642-03503-6_7. Recent Results Cancer Res. 2011. PMID: 21822823 Review.
Cited by
-
Computed tomography-based radiomics and body composition model for predicting hepatic decompensation.Oncotarget. 2024 Nov 22;15:809-813. doi: 10.18632/oncotarget.28673. Oncotarget. 2024. PMID: 39576671 Free PMC article.
-
Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.Cells. 2024 Oct 4;13(19):1650. doi: 10.3390/cells13191650. Cells. 2024. PMID: 39404413 Free PMC article. Review.
-
Astragali radix (Huangqi): a time-honored nourishing herbal medicine.Chin Med. 2024 Aug 30;19(1):119. doi: 10.1186/s13020-024-00977-z. Chin Med. 2024. PMID: 39215362 Free PMC article. Review.
-
Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis.Gastro Hep Adv. 2022 Mar 30;1(3):287-295. doi: 10.1016/j.gastha.2022.01.003. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39131684 Free PMC article.
-
CYP2E1 deficit mediates cholic acid-induced malignant growth in hepatocellular carcinoma cells.Mol Med. 2024 Jun 7;30(1):79. doi: 10.1186/s10020-024-00844-5. Mol Med. 2024. PMID: 38844847 Free PMC article.
References
-
- Berdal JE, Ebbesen J, Rydning A. Incidence and prevalence of autoimmune liver diseases. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 1998;118:4517–9. - PubMed
-
- Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571–7. - PubMed
-
- Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV, Jr, Yawn BP, Dickson ER, Melton LJ., 3rd Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364–9. - PubMed
-
- Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. The American journal of gastroenterology. 2007;102:1042–9. - PubMed
-
- Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, Kaplan GG. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:1590–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
